123 related articles for article (PubMed ID: 24291621)
1. Re-examining the role of high-dose chemotherapy in the treatment of light chain amyloidosis.
Devine SM
Biol Blood Marrow Transplant; 2014 Jan; 20(1):14-9. PubMed ID: 24291621
[No Abstract] [Full Text] [Related]
2. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
3. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
4. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
5. High-dose chemotherapy with autotransplantation in AL amyloidosis: a flawed meta-analysis.
Mehta J; Dispenzieri A; Gertz MA
Biol Blood Marrow Transplant; 2010 Jan; 16(1):138-40; author reply 140-1. PubMed ID: 19761864
[No Abstract] [Full Text] [Related]
6. Renal response after high-dose melphalan and stem cell transplantation is a favorable marker in patients with primary systemic amyloidosis.
Leung N; Dispenzieri A; Fervenza FC; Lacy MQ; Villicana R; Cavalcante JL; Gertz MA
Am J Kidney Dis; 2005 Aug; 46(2):270-7. PubMed ID: 16112045
[TBL] [Abstract][Full Text] [Related]
7. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
8. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
Cohen AD; Zhou P; Chou J; Teruya-Feldstein J; Reich L; Hassoun H; Levine B; Filippa DA; Riedel E; Kewalramani T; Stubblefield MD; Fleisher M; Nimer S; Comenzo RL
Br J Haematol; 2007 Oct; 139(2):224-33. PubMed ID: 17897298
[TBL] [Abstract][Full Text] [Related]
9. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
10. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
Mignot A; Varnous S; Redonnet M; Jaccard A; Epailly E; Vermes E; Boissonnat P; Gandjbakhch I; Herpin D; Touchard G; Bridoux F
Arch Cardiovasc Dis; 2008 Sep; 101(9):523-32. PubMed ID: 19041836
[TBL] [Abstract][Full Text] [Related]
11. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial.
Sanchorawala V; Wright DG; Seldin DC; Falk RH; Finn KT; Dember LM; Berk JL; Quillen K; Anderson JJ; Comenzo RL; Skinner M
Bone Marrow Transplant; 2004 Feb; 33(4):381-8. PubMed ID: 14676787
[TBL] [Abstract][Full Text] [Related]
12. High-dose therapy and autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis: a Center for International Blood and Marrow Transplant Research Study.
Vesole DH; Pérez WS; Akasheh M; Boudreau C; Reece DE; Bredeson CN;
Mayo Clin Proc; 2006 Jul; 81(7):880-8. PubMed ID: 16835967
[TBL] [Abstract][Full Text] [Related]
13. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis.
Kristen AV; Sack FU; Schonland SO; Hegenbart U; Helmke BM; Koch A; Schnabel PA; Röcken C; Hardt S; Remppis A; Goldschmidt H; Karck M; Ho AD; Katus HA; Dengler TJ
Eur J Heart Fail; 2009 Oct; 11(10):1014-20. PubMed ID: 19789405
[TBL] [Abstract][Full Text] [Related]
14. [Autologous peripheral blood hematopoietic cell transplantation in the treatment of AL-amyloidosis].
Smirnova AG; Smirnov AV; Zander A; Afanas'ev BV
Ter Arkh; 2010; 82(10):61-4. PubMed ID: 21341467
[TBL] [Abstract][Full Text] [Related]
15. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
Jaccard A; Moreau P; Leblond V; Leleu X; Benboubker L; Hermine O; Recher C; Asli B; Lioure B; Royer B; Jardin F; Bridoux F; Grosbois B; Jaubert J; Piette JC; Ronco P; Quet F; Cogne M; Fermand JP;
N Engl J Med; 2007 Sep; 357(11):1083-93. PubMed ID: 17855669
[TBL] [Abstract][Full Text] [Related]
16. [Clinical investigation of primary amyloidosis with autologous hematopoietic stem cell transplantation].
Qiu ZX; Wang MJ; Wang LH; Sun YH; Xu WL; Liu W; Ou JP; Dong YJ; Wang WS; Li Y; Yin Y; Liang ZY; Cen XN; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):187-90. PubMed ID: 22781604
[TBL] [Abstract][Full Text] [Related]
17. Autologous stem-cell transplantation in progressing amyloidosis is associated with severe transplant-related toxicity.
Worel N; Schulenburg A; Mitterbauer M; Keil F; Rabitsch W; Kalhs P; Gisslinger H; Raderer M; Geissler K; Höcker P; Zielinski CC; Oberbauer R; Greinix HT
Wien Klin Wochenschr; 2006 Feb; 118(1-2):49-53. PubMed ID: 16489526
[TBL] [Abstract][Full Text] [Related]
18. Using Novel Agents and Stem Cell Transplantation to Optimally Manage Immunoglobulin Light Chain Amyloidosis.
Gertz MA
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1339-40. PubMed ID: 25899453
[No Abstract] [Full Text] [Related]
19. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Sher T; Hayman SR; Gertz MA
Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
[TBL] [Abstract][Full Text] [Related]
20. High-dose melphalan and autologous hematopoietic stem cell transplantation in primary amyloidosis: single-center results.
Charlinski G; Ziarkiewicz M; Boguradzki P; Wiater E; Torosian T; Dwilewicz-Trojaczek J; Wiktor-Jedrzejczak W
Transplant Proc; 2014 Oct; 46(8):2877-81. PubMed ID: 25380940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
